Prevalence of Hepatitis B Virus Infection Among General Population of Armenia in 2021 and Factors Associated with It: a Cross-sectional Study

Overview

Journal BMJ Open

Specialty General Medicine

Date 2024 Feb 7

PMID 38326250

Authors

Anahit Demirchyan

Sandra Dudareva

Serine Sahakyan

Lusine Aslanyan

Diana Muradyan

Lusine Musheghyan

Antons Mozalevskis

Narina Sargsyants

Gayane Ghukasyan

Varduhi Petrosyan

Affiliations

Soon will be listed here.

Abstract

Objectives: This study sought to determine the prevalence and associated factors of hepatitis B virus (HBV) infection ever in life and chronic HBV infection in Armenia.

Design: A population-based cross-sectional seroprevalence study combined with a phone survey of tested individuals.

Setting: All administrative units of Armenia including 10 provinces and capital city Yerevan.

Participants: The study frame was the general adult population of Armenia aged ≥18 years.

Primary And Secondary Outcome Measures: The participants were tested for anti-HBV core antibodies (anti-HBc) and HBV surface antigen (HBsAg) using third-generation enzyme immunoassays. In case of HBsAg positivity, HBV DNA and hepatitis D virus (HDV) RNA PCR tests were performed. Risk factors of HBV infection ever in life (anti-HBc positivity) and chronic HBV infection (HBsAg positivity) were identified through fitting logistic regression models.

Results: The seroprevalence study included 3838 individuals 18 years and older. Of them, 90.7% (3476 individuals) responded to the phone survey. The prevalence of anti-HBc positivity was 14.1% (95% CI 13.1% to 15.2%) and HBsAg positivity 0.8% (95% CI 0.5% to 1.1%). The viral load was over 10 000 IU/mL for 7.9% of HBsAg-positive individuals. None of the participants was positive for HDV. Risk factors for HBsAg positivity included less than secondary education (aOR=6.44; 95% CI 2.2 to 19.1), current smoking (aOR=2.56; 95% CI 1.2 to 5.6), and chronic liver disease (aOR=8.44; 95% CI 3.0 to 23.7). In addition to these, risk factors for anti-HBc positivity included age (aOR=1.04; 95% CI 1.04 to 1.05), imprisonment ever in life (aOR=2.53; 95% CI 1.41 to 4.56), and poor knowledge on infectious diseases (aOR=1.32; 95% CI 1.05 to 1.67), while living in Yerevan (vs provinces) was protective (aOR=0.74; 95% CI 0.59 to 0.93).

Conclusion: This study provided robust estimates of HBV markers among general population of Armenia. Its findings delineated the need to revise HBV testing and treatment strategies considering higher risk population groups, and improve population knowledge on HBV prevention.

Citing Articles

An In-Depth Approach to the Associations between MicroRNAs and Viral Load in Patients with Chronic Hepatitis B-A Systematic Review and Meta-Analysis.

Manea M, Maruntelu I, Constantinescu I Int J Mol Sci. 2024; 25(15).

PMID: 39125978 PMC: 11313658. DOI: 10.3390/ijms25158410.

References

Brown R, Goulder P, Matthews P . Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Res. 2022; 7:32. PMC: 9520633. DOI: 10.12688/wellcomeopenres.17601.2. View

Kim G, Han S, Choi G, Choi J, Lim Y . Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther. 2020; 51(11):1169-1179. DOI: 10.1111/apt.15725. View

MacLachlan J, Cowie B . Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015; 5(5):a021410. PMC: 4448582. DOI: 10.1101/cshperspect.a021410. View

Wang H, Men P, Xiao Y, Gao P, Lv M, Yuan Q . Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis. 2019; 19(1):811. PMC: 6751646. DOI: 10.1186/s12879-019-4428-y. View

Pattyn J, Hendrickx G, Vorsters A, Van Damme P . Hepatitis B Vaccines. J Infect Dis. 2021; 224(12 Suppl 2):S343-S351. PMC: 8482019. DOI: 10.1093/infdis/jiaa668. View

. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018; 3(6):383-403. DOI: 10.1016/S2468-1253(18)30056-6. View

Ruggieri A, Gagliardi M, Anticoli S . Sex-Dependent Outcome of Hepatitis B and C Viruses Infections: Synergy of Sex Hormones and Immune Responses?. Front Immunol. 2018; 9:2302. PMC: 6186821. DOI: 10.3389/fimmu.2018.02302. View

Tosun S, Aygun O, Ozkan Ozdemir H, Korkmaz E, Ozdemir D . The impact of economic and social factors on the prevalence of hepatitis B in Turkey. BMC Public Health. 2018; 18(1):649. PMC: 5964685. DOI: 10.1186/s12889-018-5575-6. View

. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2023; 8(10):879-907. DOI: 10.1016/S2468-1253(23)00197-8. View

10.

Davlidova S, Haley-Johnson Z, Nyhan K, Farooq A, Vermund S, Ali S . Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus: A systematic review. Int J Infect Dis. 2021; 104:510-525. PMC: 11094609. DOI: 10.1016/j.ijid.2020.12.068. View

11.

Hou J, Liu Z, Gu F . Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci. 2005; 2(1):50-57. PMC: 1142225. DOI: 10.7150/ijms.2.50. View

12.

Barcena Marugan R, Garcia Garzon S . DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol. 2009; 15(4):423-30. PMC: 2653363. DOI: 10.3748/wjg.15.423. View

13.

Liu C, Chen B, Chen P, Lai M, Huang W, Kao J . Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis. 2006; 193(9):1258-65. DOI: 10.1086/502978. View

14.

Corona R, CAPRILLI F, Giglio A, Stroffolini T, Tosti M, Gentili G . Risk factors for hepatitis B virus infection among heterosexuals attending a sexually transmitted diseases clinic in Italy: role of genital ulcerative diseases. J Med Virol. 1996; 48(3):262-6. DOI: 10.1002/(SICI)1096-9071(199603)48:3<262::AID-JMV8>3.0.CO;2-6. View

15.

Brodzinski A, Neumeyer-Gromen A, Dudareva S, Zimmermann R, Latza U, Bremer V . [Hepatitis B virus infection and vaccine-induced immunity: the role of sociodemographic determinants : Results of the study "German Health Interview and Examination Survey for Adults" (DEGS1, 2008-2011)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021; 65(2):159-169. PMC: 8813829. DOI: 10.1007/s00103-021-03473-z. View

16.

Terrault N, Wahed A, Feld J, Cooper S, Ghany M, Lisker-Melman M . Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohort. Hepatology. 2021; 75(3):709-723. PMC: 8943823. DOI: 10.1002/hep.32231. View

17.

Tseng T, Liu C, Yang H, Su T, Wang C, Chen C . High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012; 142(5):1140-1149.e3. DOI: 10.1053/j.gastro.2012.02.007. View

18.

. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022; 7(9):796-829. PMC: 9349325. DOI: 10.1016/S2468-1253(22)00124-8. View

19.

Pereira L, Martelli C, Merchan-Hamann E, Montarroyos U, Braga M, de Lima M . Population-based multicentric survey of hepatitis B infection and risk factor differences among three regions in Brazil. Am J Trop Med Hyg. 2009; 81(2):240-7. View

20.

Ott J, Stevens G, Groeger J, Wiersma S . Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12):2212-9. DOI: 10.1016/j.vaccine.2011.12.116. View